Innovating oncology evidence generation through new endpoints

At a time when the bar for safety and efficacy of new cancer drugs continues to rise, the ability to capture nuances in clinical data can be the difference between positive and negative results. That’s where novel endpoints such as treatment failure-free survival come into play.

Oncology has some of the industry’s most established clinical endpoints, and in many cases, overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) are still sufficient for evidence generation...